MedTrace Logo

Olaparib in Patients With HRD Malignant Mesothelioma

NCT04515836 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-05-06

No results posted yet for this study

Summary

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

Conditions

Interventions

DRUG

Olaparib

Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Hedy L Kindler, MD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-19
Primary Completion
2028-04-15
Completion
2028-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04515836 on ClinicalTrials.gov